The U.S. FDA approved Vera Therapeutics’ Trutakna (atacicept) for immunoglobulin A nephropathy (IgAN), making it the first dual BAFF/APRIL inhibitor cleared for the condition. The accelerated approval supports use in reducing proteinuria in adults with primary IgAN at risk of disease progression, administered once weekly via auto-injector. Vera said the clearance arrives on the July 7 PDUFA date and sets up a commercial head start relative to Vertex, which has also been active in the IgAN competitive landscape. The accelerated approval is based on proteinuria reduction, with longer-term confirmatory work needed to determine impact on kidney function decline. A confirmatory study, Origin 3, is already underway with results expected in the third quarter, which Vera said could shape a potential full approval path.